Company news

Recursion Pharmaceuticals, Inc. news in 2024

Recursion Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

December 19, 2024

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

December 8, 2024

Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma

December 2, 2024

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

November 19, 2024

Recursion and Exscientia Shareholders Approve the Proposed Combination

November 12, 2024

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden

November 11, 2024

Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results

November 5, 2024

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

October 29, 2024

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

October 21, 2024

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

October 1, 2024

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

September 2, 2024

Recursion updates L(earnings) call on August 8th to 8: 30 am ET / 6: 30 am MT

August 7, 2024

Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

August 7, 2024

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

August 7, 2024

Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th

August 4, 2024

Recursion Announces Proposed Offering of Class A Common Stock

June 25, 2024

Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock

June 25, 2024

Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool

May 28, 2024

Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board

May 23, 2024

Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry

May 12, 2024

Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results

May 8, 2024

Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9

May 1, 2024

Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer

April 15, 2024

Recursion Publishes Annual Environmental, Social and Governance Report

March 25, 2024

Recursion Announces Plans to Open New Office in London

March 10, 2024

Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community

February 29, 2024

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results

February 26, 2024

Recursion to Host Public L(earnings) Call on February 27

February 19, 2024

Recursion Unveils LOWE Drug Discovery Software at the J.P. Morgan Healthcare Conference

January 7, 2024

Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline

January 3, 2024

Recursion to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8

January 2, 2024

Calls in 2024

Decks in 2024